Literature DB >> 15565603

Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels.

Bernd Kronenberger1, Eva Herrmann, Florence Micol, Michael von Wagner, Stefan Zeuzem.   

Abstract

The aim of the present study was to compare viral kinetics between patients with chronic hepatitis C and persistently normal alanine aminotransferase (ALT) levels and those with elevated ALT levels. Kinetic parameters were derived from nonlinear, least square fitting of serum hepatitis C virus RNA quantifications collected from patients with chronic hepatitis C and persistently normal (n = 20) and elevated (n = 19) ALT levels before and during treatment with 180 mug pegylated interferon alpha-2a once weekly plus daily ribavirin. Patients with chronic hepatitis C and persistently normal ALT levels showed a trend to lower pretreatment infected cell loss (delta) (P = .13) but no differences in efficacy of blocking virus production (epsilon) and infected cell loss during treatment (mdelta) compared with patients with elevated ALT levels. Differences were significant for epsilon (P = .02) and delta (P = .04) when applying updated "healthy" levels for ALT (0.75 times and 0.63 times upper limit of normal for male and female patients, respectively). A significant reduction of the kinetic parameters epsilon, delta, and mdelta was observed in patients with elevated gamma-glutamyltranspeptidase (GGT) levels compared with patients with normal GGT levels (P = .02, P = .005, and P = .02, respectively). In conclusion, viral kinetics are similar in patients with chronic hepatitis C and persistently normal ALT levels and those with elevated ALT levels. However, in patients with elevated GGT levels, a major association with reduced efficacy of blocking virus production and lower infected cell loss was observed. These data show that virological response in patients with chronic hepatitis C is less associated with baseline ALT than with GGT levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15565603     DOI: 10.1002/hep.20487

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

Review 1.  Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels.

Authors:  Gillian M Keating; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients.

Authors:  Joseph K Lim; Janet P Tate; Shawn L Fultz; Joseph L Goulet; Joseph Conigliaro; Kendall J Bryant; Adam J Gordon; Cynthia Gibert; David Rimland; Matthew Bidwell Goetz; Marina B Klein; David A Fiellin; Amy C Justice; Vincent Lo Re
Journal:  Clin Infect Dis       Date:  2014-02-25       Impact factor: 9.079

Review 3.  Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Rosa Zampino; Margherita Macera; Caterina Sagnelli; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

4.  The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection.

Authors:  Viola Weich; Eva Herrmann; Tje Lin Chung; Christoph Sarrazin; Holger Hinrichsen; Peter Buggisch; Tilman Gerlach; Hartwig Klinker; Ulrich Spengler; Alexandra Bergk; Stefan Zeuzem; Thomas Berg
Journal:  J Gastroenterol       Date:  2011-09-13       Impact factor: 7.527

5.  Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors.

Authors:  Verónica Saludes; Maria Alma Bracho; Oliver Valero; Mercè Ardèvol; Ramón Planas; Fernando González-Candelas; Vicente Ausina; Elisa Martró
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

6.  Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.

Authors:  Valeria Cento; Thi Huyen Tram Nguyen; Domenico Di Carlo; Elisa Biliotti; Laura Gianserra; Ilaria Lenci; Daniele Di Paolo; Vincenza Calvaruso; Elisabetta Teti; Maddalena Cerrone; Dante Romagnoli; Michela Melis; Elena Danieli; Barbara Menzaghi; Ennio Polilli; Massimo Siciliano; Laura Ambra Nicolini; Antonio Di Biagio; Carlo Federico Magni; Matteo Bolis; Francesco Paolo Antonucci; Velia Chiara Di Maio; Roberta Alfieri; Loredana Sarmati; Paolo Casalino; Sergio Bernardini; Valeria Micheli; Giuliano Rizzardini; Giustino Parruti; Tiziana Quirino; Massimo Puoti; Sergio Babudieri; Antonella D'Arminio Monforte; Massimo Andreoni; Antonio Craxì; Mario Angelico; Caterina Pasquazzi; Gloria Taliani; Jeremie Guedj; Carlo Federico Perno; Francesca Ceccherini-Silberstein
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.